Target
VEGFR 2
3 abstracts
Abstract
A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma.Org: UPMC Hillman Cancer Center, Pittsburgh, PA, UT Health Science Center at San Antonio, Mays Cancer Center, San Antonio, TX,
Abstract
Surufatinib combined with TAS-102 in third- or later-line therapy of patients with metastatic pancreatic cancer (mPDAC): An open-label, single-arm, phase II study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,
Abstract
Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial.Org: 3rd Affiliated Hospital of ZhengZhou University,